Featured Story | March 2018
Could the ORBITA trial’s enduring value be in prompting the cardiology community to rethink how it diagnoses, treats and even defines angina?
Thumbnail
Could the ORBITA trial’s enduring value be in prompting the cardiology community to rethink how it diagnoses, treats and even defines angina?
Thumbnail
“In a business that’s constantly changing, there are always areas for improvement,” said Cathleen Biga, RN, MSN, a member of the Cardiovascular Business editorial advisory board. Cathie shared the sentiment with my colleague Daniel Allar, who was interviewing her about the upcoming American College of Cardiology Cardiovascular Summit that she co-directs and we’ll be attending.
Thumbnail
Taking call is hardly a new burden for cardiologists, but emerging trends as well as evolving attitudes are taking some of the sting out of the obligation.
Thumbnail
A small but growing number of survivorship clinics for congenital heart disease (CHD) patients are popping up in healthcare systems across the country, but some cardiologists wonder if the model is sustainable.
Thumbnail
Paying for call coverage isn’t always an option and, even when it is, sometimes it’s more bandage than cure. The priority should be addressing long-term physician satisfaction.
Thumbnail
Program planners predict shared decision making (SDM) will be a hot topic when the American College of Cardiology (ACC) hosts its 2018 Scientific Session March 10-12 in Orlando. They’ve planned a two-part intensive, as well as several other sessions, around the subject.
Thumbnail
Known for its conservative and what many call risk-averse nature, the Food and Drug Administration (FDA) seems to be headed in a bold and ambitious direction under Commissioner Scott Gottlieb, MD. What will his leadership mean for cardiology?
Thumbnail
The cardiology community is paying close attention to developments related to transcatheter mitral valve replacement (TMVR) for mitral regurgitation. Although TMVR is in its infancy, one big question on everyone’s minds is whether its impact will be on the same scale as transcatheter aortic valve replacement (TAVR).
Thumbnail
The days of physicians saying, “I want this” are fading fast, if not gone, in many locations, as hospitals restructure purchasing around committee decision making and formal processes.
Thumbnail
Peer-to-peer support benefits patients, but the model needs to change rapidly to keep up with treatment innovations.